Terms of Reference

RCOG logo

 

 

  

  1. Identify the cases of cervical cancer screened by the CervicalCheck programme whose cervical screening history needs to be examined and whose cytology history needs to be reviewed.
     
  2. Review the screening, cytological and clinical history(case notes) of those women, a) who are identified as discordant cytology results, and b) those who had colposcopic management more than six months prior to cancer diagnosis.
     
  3. To determine in those cases with discordant results, what was the impact on treatment, prognosis and outcome.
     
  4. To determine in those with colposcopy prior to six months before cancer diagnosis, that this did not contribute to a failure to prevent cancer.
     
  5. Provide for the HSE's CervicalCheck screening programme an individual written report on each individual case.
     
  6. The HSE CervicalCheck screening programme will be responsible, through the appropriate healthcare professional, for sharing these reports with individual women unless she expresses a wish not to be informed.
     
  7. Produce an aggregated anonymised report for the Minister for Health for publication which shall include recommendations where appropriate, with the aim of improving care for women. 
     
  8. Participate in engagement with the Irish clinical community, and where appropriate in forums with affected women about the findings of the review panel. Engage as appropriate with the Scoping Inquiry into the CervicalCheck Screening Programme being led by Dr Gabriel Scally.
     
  9. The panel could engage with individual women regarding the facts and interpretation of their case review, but expressly not to discuss any aspects of an individual woman’s clinical care.